ODC1 and neoplasm: One approach may involve nanoparticle encapsulation of, or conjugation with, DFMO and other polyamine analogs to deliver and accumulate the drugs within the tumor [2]; however, Wu et al. demonstrated that Odc deletion in T cells did not affect proliferation in vivo, likely due to compensatory mechanisms [18]; perhaps systemic DFMO would not significantly inhibit immune proliferation.